Emd Serono Inc Drug Patent Portfolio
Emd Serono Inc owns 4 orange book drugs protected by 18 US patents Given below is the list of Emd Serono Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10849919 | Cladribine regimen for treating progressive forms of multiple sclerosis | 23 Nov, 2038 | Active |
| US8580781 | Pyridazinone derivatives | 19 Mar, 2030 | Active |
| US8329692 | Pyrimidinyl pyridazinone derivatives | 30 Oct, 2029 | Active |
| US8927540 | Pyridazinone derivatives | 21 Jul, 2028 | Active |
| US8658643 | Pyrimidinyl pyridazinone derivatives | 04 Jul, 2028 | Active |
| US9062029 | Pyrimidinyl pyridazinone derivatives | 04 Jul, 2028 | Active |
| US9403799 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | 04 Jul, 2028 | Active |
| US8921357 | Pyridazinone derivatives | 30 May, 2028 | Active |
| US9284300 | Pyridazinone derivatives | 29 Apr, 2028 | Active |
| US7713947 | Cladribine regimen for treating multiple sclerosis | 16 Oct, 2026 | Active |
| US8377903 | Cladribine regimen for treating multiple sclerosis | 31 May, 2026 | Active |
| US7888328 | Oral formulations of cladribine | 11 Apr, 2024 | Expired |
| US8785415 | Oral formulations of cladribine | 11 Apr, 2024 | Expired |
| US6319192 | Method for the treatment of fertility disorders | 23 Apr, 2019 | Expired |
| US6475521 | Biphasic controlled release delivery system for high solubility pharmaceuticals and method | 19 Mar, 2018 | Expired |
| US6660300 | Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method | 19 Mar, 2018 | Expired |
| US6863891 | Oligopeptide lyophilisate, their preparation and use | 22 Feb, 2014 | Expired |
| US7605121 | Oligopeptide lyophilisate, their preparation and use | 22 Feb, 2014 | Expired |
Latest Legal Activities on Emd Serono Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Emd Serono Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2024 | US8329692 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849919 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2024 | US9403799 |
|
Request for Trial Granted
Critical
| 20 Dec, 2023 | US8377903 |
| Mail-Petition Decision - Denied | 20 Dec, 2023 | US7713947 |
|
Request for Trial Granted
Critical
| 20 Dec, 2023 | US7713947 |
| Petition Entered | 19 Dec, 2023 | US7713947 |
| Petition Decision - Denied | 19 Dec, 2023 | US7713947 |
|
Request for Trial Granted
Critical
| 22 Sep, 2023 | US8377903 |
|
Request for Trial Granted
Critical
| 22 Sep, 2023 | US7713947 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Aug, 2023 | US9284300 |
| Termination or Final Written Decision | 16 Aug, 2023 | US10849919 |
|
Electronic Review
Critical
| 10 May, 2023 | US8377903 |
|
Electronic Review
Critical
| 05 May, 2023 | US8377903 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 13 Apr, 2023 | US8377903 |
Emd Serono Inc's Drug Patent Litigations
Emd Serono Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 10, 2023, against patent number US10849919. The petitioner Hopewell Pharma Ventures, Inc. et al., challenged the validity of this patent, with Ares Trading SA as the respondent. Click below to track the latest information on how companies are challenging Emd Serono Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7713947 | October, 2022 |
Trial Instituted
(20 Dec, 2023)
| Merck Serono SA | TWi Pharmaceuticals, Inc. |
| US8377903 | October, 2022 |
Trial Instituted
(20 Dec, 2023)
| Merck Serono SA | TWi Pharmaceuticals, Inc. |
| US7713947 | January, 2023 |
Trial Instituted
(22 Sep, 2023)
| Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
| US8377903 | January, 2023 |
Trial Instituted
(22 Sep, 2023)
| Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
| US10849919 | February, 2023 |
Terminated-Settled
(16 Aug, 2023)
| Ares Trading SA | Hopewell Pharma Ventures, Inc. et al. |
Emd Serono Inc Drug Patents' Oppositions Filed in EPO
Emd Serono Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 16, 2018, by Generics (Uk) Ltd. This opposition was filed on patent number EP14001970A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP14001970A | Oct, 2018 | Generics (UK) Ltd | Granted and Under Opposition |
Emd Serono Inc's Family Patents
Emd Serono Inc Drug List
Given below is the complete list of Emd Serono Inc's drugs and the patents protecting them.
1. Cetrotide
Cetrotide is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6319192 | Method for the treatment of fertility disorders |
23 Apr, 2019
(5 years ago)
| Expired |
| US6863891 | Oligopeptide lyophilisate, their preparation and use |
22 Feb, 2014
(10 years ago)
| Expired |
| US7605121 | Oligopeptide lyophilisate, their preparation and use |
22 Feb, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cetrotide's drug page
2. Glucophage Xr
Glucophage Xr is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6475521 | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
19 Mar, 2018
(6 years ago)
| Expired |
| US6660300 | Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method |
19 Mar, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glucophage Xr's drug page
3. Mavenclad
Mavenclad is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10849919 | Cladribine regimen for treating progressive forms of multiple sclerosis |
23 Nov, 2038
(14 years from now)
| Active |
| US7713947 | Cladribine regimen for treating multiple sclerosis |
16 Oct, 2026
(1 year, 10 months from now)
| Active |
| US8377903 | Cladribine regimen for treating multiple sclerosis |
31 May, 2026
(1 year, 6 months from now)
| Active |
| US7888328 | Oral formulations of cladribine |
11 Apr, 2024
(7 months ago)
| Expired |
| US8785415 | Oral formulations of cladribine |
11 Apr, 2024
(7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavenclad's drug page
4. Tepmetko
Tepmetko is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580781 | Pyridazinone derivatives |
19 Mar, 2030
(5 years from now)
| Active |
| US8329692 | Pyrimidinyl pyridazinone derivatives |
30 Oct, 2029
(4 years from now)
| Active |
| US8927540 | Pyridazinone derivatives |
21 Jul, 2028
(3 years from now)
| Active |
| US8658643 | Pyrimidinyl pyridazinone derivatives |
04 Jul, 2028
(3 years from now)
| Active |
| US9062029 | Pyrimidinyl pyridazinone derivatives |
04 Jul, 2028
(3 years from now)
| Active |
| US9403799 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
04 Jul, 2028
(3 years from now)
| Active |
| US8921357 | Pyridazinone derivatives |
30 May, 2028
(3 years from now)
| Active |
| US9284300 | Pyridazinone derivatives |
29 Apr, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tepmetko's drug page